Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn’s disease

In the randomized, double-blind, placebo-controlled CHARM trial, adalimumab was more effective than placebo in maintaining clinical remission for patients with moderate-to-severe Crohn's disease (CD) through 56 weeks.To substantiate the long-term safety and clinical benefits of adalimumab through 2 years of therapy in CHARM and its open-label extension (ADHERE).Patients entering ADHERE on blinded therapy received adalimumab 40 mg every other...